MX2022013427A - Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer. - Google Patents
Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer.Info
- Publication number
- MX2022013427A MX2022013427A MX2022013427A MX2022013427A MX2022013427A MX 2022013427 A MX2022013427 A MX 2022013427A MX 2022013427 A MX2022013427 A MX 2022013427A MX 2022013427 A MX2022013427 A MX 2022013427A MX 2022013427 A MX2022013427 A MX 2022013427A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- disease
- methods
- subject
- agitation associated
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 238000013019 agitation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- MKXZASYAUGDDCJ-QNNIAVNKSA-N deudextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C([2H])([2H])[2H])[C@H]2CC2=CC=C(OC([2H])([2H])[2H])C=C21 MKXZASYAUGDDCJ-QNNIAVNKSA-N 0.000 abstract 2
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 abstract 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 abstract 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 1
- 229960001404 quinidine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016270P | 2020-04-27 | 2020-04-27 | |
| PCT/US2021/029246 WO2021222145A1 (en) | 2020-04-27 | 2021-04-26 | Methomethods of treating agitation associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013427A true MX2022013427A (es) | 2023-01-19 |
Family
ID=75914613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013427A MX2022013427A (es) | 2020-04-27 | 2021-04-26 | Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230270738A1 (enExample) |
| EP (1) | EP4142729A1 (enExample) |
| JP (1) | JP2023523373A (enExample) |
| KR (1) | KR20230016636A (enExample) |
| CN (1) | CN115734787A (enExample) |
| AU (1) | AU2021263354A1 (enExample) |
| BR (1) | BR112022021535A2 (enExample) |
| CA (1) | CA3176234A1 (enExample) |
| IL (1) | IL296977A (enExample) |
| MX (1) | MX2022013427A (enExample) |
| PH (1) | PH12022552764A1 (enExample) |
| TW (1) | TW202203922A (enExample) |
| WO (1) | WO2021222145A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2792662T3 (da) | 2007-05-01 | 2016-07-25 | Concert Pharmaceuticals Inc | Morphinanforbindelser |
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| KR20240110812A (ko) * | 2021-10-27 | 2024-07-16 | 아바니르 파마슈티컬스, 인코포레이티드 | 알츠하이머병과 관련된 불안을 치료하는 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| US20160143901A1 (en) * | 2006-02-03 | 2016-05-26 | Avanir Pharmaceuticals, Inc. | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia |
| MX370608B (es) | 2007-05-01 | 2019-12-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| TWI869633B (zh) * | 2014-09-14 | 2025-01-11 | 美商阿瓦尼爾製藥股份有限公司 | 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物 |
-
2021
- 2021-04-26 WO PCT/US2021/029246 patent/WO2021222145A1/en not_active Ceased
- 2021-04-26 EP EP21725652.8A patent/EP4142729A1/en not_active Withdrawn
- 2021-04-26 JP JP2023509465A patent/JP2023523373A/ja active Pending
- 2021-04-26 CA CA3176234A patent/CA3176234A1/en active Pending
- 2021-04-26 CN CN202180045685.XA patent/CN115734787A/zh active Pending
- 2021-04-26 BR BR112022021535A patent/BR112022021535A2/pt not_active IP Right Cessation
- 2021-04-26 PH PH1/2022/552764A patent/PH12022552764A1/en unknown
- 2021-04-26 MX MX2022013427A patent/MX2022013427A/es unknown
- 2021-04-26 AU AU2021263354A patent/AU2021263354A1/en not_active Abandoned
- 2021-04-26 KR KR1020227041229A patent/KR20230016636A/ko active Pending
- 2021-04-26 US US17/921,579 patent/US20230270738A1/en not_active Abandoned
- 2021-04-26 IL IL296977A patent/IL296977A/en unknown
- 2021-04-27 TW TW110115202A patent/TW202203922A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4142729A1 (en) | 2023-03-08 |
| IL296977A (en) | 2022-12-01 |
| WO2021222145A1 (en) | 2021-11-04 |
| BR112022021535A2 (pt) | 2023-01-24 |
| US20230270738A1 (en) | 2023-08-31 |
| KR20230016636A (ko) | 2023-02-02 |
| TW202203922A (zh) | 2022-02-01 |
| WO2021222145A8 (en) | 2021-12-30 |
| PH12022552764A1 (en) | 2024-03-25 |
| AU2021263354A1 (en) | 2022-10-27 |
| JP2023523373A (ja) | 2023-06-02 |
| CN115734787A (zh) | 2023-03-03 |
| CA3176234A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552764A1 (en) | Methods of treating agitation associated with alzheimer`s disease | |
| FRUMESS et al. | Light-sensitive seborrheid | |
| JP2023541048A5 (enExample) | ||
| EA202193178A1 (ru) | Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина | |
| MX2024005154A (es) | Métodos de tratamiento de la agitación asociada a la enfermedad de alzheimer. | |
| MX2021013807A (es) | Tratamiento de enfermedad ocular. | |
| Mathan et al. | Olanzapine-induced tender pitting pre-tibial edema | |
| MX2024002567A (es) | Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. | |
| Williams et al. | Percutaneous ultrasonic tenotomy for refractory common extensor tendinopathy after failed open surgical release: a report of two cases | |
| Gilligan et al. | Amantadine hydrochloride in the treatment of Parkinson's disease | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| Pratiwi | The Implementation of Valsava Manuever on Pain Reduction During IV Cannulation: A literature review | |
| Winstock et al. | Dental extractions in haemophilia: plasma therapy without dental splints | |
| Djanayev et al. | DRUGS USED IN PARKINSON'S (LITERATURE REVIEW). | |
| Long | Penicillin and Diphtheria | |
| Cockerham | Correspondence: Australian National Heart Foundation | |
| TÃTARU et al. | DIABETES MELLITUS AND THE SKIN. | |
| 주성범 | Effect of Kinesio Taping with Magnets on the Pain Level of Patients with Chronic Lower Back Pain | |
| Tian et al. | Pretibial myxedema, white fibrous papulosis, eruptive syringomas: a hypothyroidism case report. | |
| Nelson | hIeesmann, _. I, and Bruhn. A. Trachoma treatment with sulfona-mides. Klin. hl. f. Augenh., 1943, v. 108, July-Aug., p. 464. Vp to 1940 only a negligible number | |
| Wilensky et al. | Thrombo-angiitis obliterans in sisters | |
| Nahas et al. | The clinical use of THAM | |
| McIntosh | Assistants and the Bill | |
| Forrest | The Health Service Bill | |
| Trousseau | 10065, USA e-mail: tjfahey@ med. cornell. edu MD Moore General Surgery, New York Hospital Weill-Cornell Medical Center, New York, NY, USA |